New Study Shows the Rate of Drug Approvals Lower than Previously ReportedJan 9 2014
Nature Biotechnology published a peer-reviewed paper co-authored by the BIO Industry Analysis and BioMedTracker (BMT) highlighting results of a study showing that the overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2011 is near one in 10.
|
|
BIO Lauds Funding Request for Military Biofuel ProgramJan 7 2014
BIO today echoed the request by the Secretaries of Energy, Agriculture and the Navy for funding and transfer authority for the Department of Energy to participate in the public-private partnership to commercialize biofuels for military use.
|
|
BIO Announces Presenting Companies for 16th Annual BIO CEO & Investor ConferenceDec 19 2013
More than 140 Companies Expected to Present Their Story to Top Public and Venture Capital Investors
|
|
BIO Supports Budget Action to Free Up FDA User FeesDec 13 2013
BIO applauds the House of Representatives for passing a bipartisan budget deal, which raises discretionary budget caps, which should provide the Food and Drug Administration with complete access to its user fees for FYs '14 and '15.
|
|
OncoMed Pharmaceuticals CEO Testifies on behalf of BIO at Congressional Hearing on FDA Drug Development and Manufacturing ChallengesDec 12 2013
Hastings highlighted the need to advance the regulatory environment so that it fosters biopharma innovation. Among his recommendations, Hastings emphasized the need to eliminate the sequestration of industry user fees and expedite drug development for serious and life-threatening diseases by expanding the existing Accelerated Approval pathway and by facilitating the new Breakthrough Therapy Designation process.
|
|
16th Annual BIO CEO & Investor Conference to Feature Fireside Chats Between Biopharma CEOs and Wall Street AnalystsDec 12 2013
BIO announced this year’s Fireside Chats lineup for the 16th annual BIO CEO & Investor Conference. The chats will feature a set of candid, one-on-one conversations between biopharma leaders and analysts, followed by an interactive question and answer session.
|
|
EPA’s 2014 RFS Proposal Will Undercut Development of Advanced and Cellulosic Biofuels, BIO SaysDec 5 2013
BIO's testimony to the EPA public hearing for the 2014 RFS volumes highlighted the jobs, investments and environmental benefits that will be lost if biofuel volumes are rolled back.
|
|
The AgAccord®: Data Use and Compensation Agreement is Open for SignatureDec 4 2013
BIO and the American Seed Trade Association (ASTA) announced today that the Data Use and Compensation Agreement (DUCA) is open for signature.
|
|
BIO Statement regarding the Innovation Act, H.R. 3309Dec 3 2013
BIO issued the following statement regarding the Innovation Act (H.R. 3309), as reported by the House Judiciary Committee.
|
|
BIO Praises Senate for Passing Single, Uniform and National Traceability SystemNov 18 2013
BIO commends the Senate for approving H.R. 3204, the Drug Quality and Security Act.
|
